Signet

$XTALPI(02228.HK) Without a doubt, Signet, invested and incubated by Jingtai Technology, has become a candidate for the Prix Galien 2025 with the world's first targeted drug for Diffuse Gastric Cancer (DGC). This is a major event for China's innovative drug industry. Here’s a summary of relevant information: About the Prix Galien USA Award Introduction Project Content Award Positioning The top life sciences innovation award in the U.S., established in 2007...